Designation of Carglumic Acid (Udecane) as an Orphan Drug

Overview

The Therapeutic Goods Act 1989 was enacted to ensure the safety, quality, and efficacy of therapeutic goods in Australia, thereby protecting public health. This Act provides the framework for the regulation of therapeutic goods, including medicines, medical devices, and blood and blood components. One of the Act's key objectives is to facilitate access to orphan drugs, which are medications developed for the treatment of rare diseases. The Therapeutic Goods Administration (TGA) is the executive arm of the Commonwealth of Australia responsible for the administration and enforcement of the Act. The designation of Carglumic acid (Udecane) as an orphan drug under the Act is intended to address the specific needs of patients with rare conditions such as hyperammonaemia due to N-acetylglutamate synthase primary deficiency and various organic acidaemias. This designation underscores the policy objective of the TGA to promote and support the development and availability of treatments for rare diseases, ultimately aiming to improve the health outcomes of affected individuals.

Scope and Application

The Therapeutic Goods Act 1989 applies to the designation of therapeutic goods within Australia, with this particular Gazette serving to designate Carglumic acid (Udecane) as an orphan drug for specified medical conditions. This Act falls under the jurisdiction of the Commonwealth of Australia and is administered by the Therapeutic Goods Administration, a division of the Department of Health. The Act applies to the sponsor of the drug, in this case Orpharma Pty Ltd, and specifies the conditions for which Carglumic acid (Udecane) can be used, namely hyperammonaemia due to N-acetylglutamate synthase deficiency and various organic acidaemias. The geographic reach of the Act is national, extending across all states and territories of Australia. The designation of Carglumic acid (Udecane) as an orphan drug allows for certain incentives and regulatory flexibility under the Therapeutic Goods Regulations 1990, including streamlined approval processes and potential financial benefits for the sponsor. The Act does not specify any exclusions or exemptions relevant to this particular designation but allows for further regulation and conditions to be set through subordinate instruments.

Key Provisions

The main operative sections of this legislation pertain to the designation of Carglumic acid (Udecane) as an orphan drug for specific medical conditions. Under section 16J of the Therapeutic Goods Regulations 1990, Dr Anthony Gill, as the Delegate of the Secretary, designates Carglumic acid (Udecane) for treating hyperammonaemia due to N-acetylglutamate synthase primary deficiency, as well as hyperammonaemia caused by various organic acidaemias, including isovaleric, methylmalonic, and propionic acidaemias (sections 16J(2)). The drug is specified in the form of dispersible tablets. This designation is effective from 11 October 2016, and the sponsor of the drug, as indicated, is Orpharma Pty Ltd. The Act imposes several obligations on the parties it governs. Firstly, the sponsor of the therapeutic good, in this case, Orpharma Pty Ltd, must ensure that Carglumic acid (Udecane) meets all regulatory requirements for an orphan drug designation. This includes providing sufficient evidence and data to support the therapeutic claims and safety of the drug for the specified indications. The sponsor must also adhere to the regulations governing the manufacturing, distribution, and marketing of therapeutic goods in Australia. Additionally, the sponsor must maintain records and be prepared to provide documentation to the Therapeutic Goods Administration upon request. There are no specific offences, penalties, or civil/criminal consequences outlined in the text for breach of the orphan drug designation requirements. However, failure to comply with the broader regulatory requirements of the Therapeutic Goods Act 1989 and the Therapeutic Goods Regulations 1990 can lead to various penalties. These may include fines, imprisonment, or both, depending on the severity of the breach. For instance, under section 32 of the Therapeutic Goods Act 1989, an individual or entity found guilty of contravening the Act could face fines of up to $222,200 for a corporation and $44,440 for an individual, or imprisonment for up to two years, or both. Additionally, the Therapeutic Goods Administration has the authority to take enforcement actions such as product recalls, suspension of manufacturing authorisations, or legal proceedings against non-compliant entities.